Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
Investigational New Drugs|October 29, 2008
Pemetrexed combined with paclitaxel: a dose-finding study evaluating three schedules in solid tumorsAxel-R Hanauske, Herlinde Dumez, Martine Piccart, et al.
Clinical Pharmacology in Drug Development|July 23, 2020
Effect of Hepatic Impairment on Cobimetinib Pharmacokinetics: The Complex Interplay Between Physiological Changes and Drug CharacteristicsSravanthi Cheeti, Yuzhong Deng, Ilsung Chang, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 4, 2009
Carboplatin and paclitaxel in combination with oral enzastaurin in advanced ovarian or primary peritoneal cancer: results from a safety lead-in studyIgnace Vergote, Frederic Amant, Gülten Oskay-Oezcelik, et al.
Neuro-Oncology|February 13, 2010
A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomasTeri N Kreisl, Svetlana Kotliarova, John A Butman, et al.
Cancer Chemotherapy and Pharmacology|January 27, 2016
A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activitiesDan Lu, Tong Lu, Mark Stroh, et al.
Cancer Chemotherapy and Pharmacology|September 2, 2021
Single- and multiple-dose pharmacokinetics, potential for CYP3A inhibition, and food effect in patients with cancer and healthy subjects receiving ipatasertibVikram Malhi, Nageshwar Budha, Rucha Sane, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 29, 2021
Evaluation of Ipatasertib Interactions with Itraconazole and Coproporphyrin I and III in a Single Drug Interaction Study in Healthy SubjectsRucha S Sane, Kit Wun Kathy Cheung, Eunpi Cho, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 10, 2020
Calibrating the In Vitro-In Vivo Correlation for OATP-Mediated Drug-Drug Interactions with Rosuvastatin Using Static and PBPK ModelsRucha Sane, Kit Wun Kathy Cheung, Péter Kovács, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 15, 2019
Exposure-Response-Based Product Profile-Driven Clinical Utility Index for Ipatasertib Dose Selection in Prostate CancerRui Zhu, Bill Poland, Russ Wada, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 7, 2009
A phase I trial of enzastaurin in patients with recurrent gliomasTeri N Kreisl, Lyndon Kim, Kraig Moore, et al.
Pageof 5